Evogene
EVGN
14 hedge funds and large institutions have $1.7M invested in Evogene in 2024 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 2 increasing their positions, 4 reducing their positions, and 17 closing their positions.
9.51% more ownership
Funds ownership: 0.78% → 10.29% (+9.5%)
34% less capital invested
Capital invested by funds: $2.55M → $1.7M (-$857K)
50% less funds holding
Funds holding: 28 → 14 (-14)
50% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 4
82% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 17
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$840K |
| 2 |
RIG
Renaissance Investment Group
Lenox,
Massachusetts
|
+$43.1K |
| 3 |
BNP Paribas Financial Markets
Paris,
France
|
+$9.32K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$8.63K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
+$1.25K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LPL Financial
San Diego,
California
|
-$43.8K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$39.9K |
| 3 |
Morgan Stanley
New York
|
-$39.9K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
-$38.4K |
| 5 |
Renaissance Technologies
New York
|
-$29.1K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
CC
26
Cypress Capital
Franklin,
Tennessee
| – | -$260 | -40 | Closed |
|
27
Qube Research & Technologies (QRT)
London,
United Kingdom
| – | -$33 | -5 | Closed |
|
28
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | -$17 | -4 | -9% |
|
|
CAS
29
Coppell Advisory Solutions
Coppell,
Texas
| – | -$18 | -3 | Closed |
|
30
Toronto Dominion Bank
Toronto, Ontario,
Ontario, Canada
| – | -$130 | -2 | Closed |
|
EVGN Hedge Fund Activity: Q3 2024 in Review
14 of the 6,965 institutional investors tracked by Wall St. Rank reported a position in Evogene (EVGN) for Q3 2024, worth a combined $1.7M — down 34% from $2.55M a quarter earlier.
Sellers outnumbered buyers: 17 funds closed out of EVGN and 3 opened new positions — a net loss of 14 holders — while 4 trimmed existing stakes and 2 added.
The largest buyer was Armistice Capital, opening a new position worth an estimated $840K. The largest seller was LPL Financial, exiting entirely with an estimated $43.8K sold.
- 14 institutional investors held Evogene (EVGN) as of Q3 2024, down from 28 in Q2 2024.
- Funds reported $1.7M of Evogene stock for Q3 2024, down 34% quarter-over-quarter.
- 3 funds opened new Evogene positions in Q3 2024 and 17 closed out, a net change of -14 holders.
- The largest Evogene buyer in Q3 2024 was Armistice Capital, an estimated $840K added.
- The largest Evogene seller in Q3 2024 was LPL Financial, an estimated $43.8K sold.
Based on aggregated 13F filings for Q3 2024.